603 filings
Page 2 of 31
8-K
62seh10udax0irnb
18 May 23
Results of Operations and Financial Condition
6:57am
8-K
9ioezgx368i
10 May 23
Other Events
6:25am
8-K
2k3zm4pgj mzg870p
5 May 23
Other Events
6:56am
8-K
pi1smkgjwr
4 May 23
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
7:37am
424B5
hlc2t6y75mw0utvb
27 Feb 23
Prospectus supplement for primary offering
7:58am
8-K
37rxj5buc2
27 Feb 23
Entry into a Material Definitive Agreement
6:48am
8-K
m8sn4 ig3nupyxp3i2dc
27 Feb 23
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
6:36am
8-K
m11xs25wa2
24 Feb 23
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
9:26am
8-K
mfd0h9t 1tt3romxu58
3 Jan 23
Protalix BioTherapeutics Issues 2023 Letter to Stockholders
6:57am
8-K
xg0wwje2oi4 fp5
27 Dec 22
Other Events
4:30pm
8-K
9odty tkewio
21 Dec 22
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
4:36pm
8-K
wxrwn zn3ljuvbi
14 Nov 22
Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
7:03am
8-K
n45lu qyj8z1jmdq
1 Sep 22
Entry into a Material Definitive Agreement
4:31pm